Wound Management Technologies, Inc. Ranked Number 369 Fastest Growing Company in North America on Deloitte’s 2017 Technology Fast 500(TM)

Attributes 219 Percent Revenue Growth to Increasing Clinical Acceptance and Usage of Their Key Product, CellerateRX® Surgical Activated Collagen® Adjuvant

FORT WORTH, TX / ACCESSWIRE / January 5, 2018 / Wound Management Technologies, Inc. (OTCQB: WNDM) today announced it ranked 369 on Deloitte’s Technology Fast 500™, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in North America. Wound Management Technologies grew 219 percent during this period.

Wound Management Technologies’ Chief Financial Officer, Michael Carmena, credits the company’s 219% revenue growth to the strength of the clinical outcomes achieved with CellerateRX® Surgical and their continued investments in expanding the sales organization. Mike said, “We have continued to build our sales team including the recent additions of Jay Speelhoffer as Director, Strategic Accounts, and Zach Fleming as our new Vice President of Sales. Both Zach and Jay are tenured medical device sales leaders who will help us continue our strong revenue growth.”

Zach Fleming, Vice President of Sales, added, “We continue to invest in building our sales team and our clinical outcomes portfolio and we are excited by the passion our customers have for CellerateRX® Surgical. We also anticipate additional growth of the company with the recent launch of our newest product, HemaQuell™ Resorbable Bone Hemostat.”

“The Deloitte 2017 North America Technology Fast 500 winners underscore the impact of technological innovation and world-class customer service in driving growth, in a fiercely competitive environment,” said Sandra Shirai, vice chairman, Deloitte Consulting LLP and U.S. technology, media and telecommunications leader. “These companies are on the cutting edge and are transforming the way we do business. We extend our sincere congratulations to all the winners for achieving remarkable growth while delivering new services and experiences for their customers.”

“Emerging growth companies are powering innovation in the broader economy. The growth rates delivered by the companies on this year’s North America Technology Fast 500 ranking are a bright spot for the capital markets and a strong indicator that the emerging growth technology sector will continue to deliver a strong return on investment,” said Heather Gates, national managing director of Deloitte & Touche LLP’s emerging growth company practice. “Deloitte is dedicated to supporting the best and brightest companies of the future in the emerging growth company sector. We are proud to acknowledge the significant accomplishments of this year’s Fast 500 winners.”

About Deloitte’s 2017 Technology Fast 500™

Deloitte’s Technology Fast 500 provides a ranking of the fastest growing technology, media, telecommunications, life sciences and energy tech companies – both public and private – in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2013 to 2016.

In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company’s operating revenues. Companies must have base-year operating revenues of at least $50,000 USD, and current-year operating revenues of at least $5 million USD. Additionally, companies must be in business for a minimum of four years and be headquartered in North America.

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee (“DTTL”), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as “Deloitte Global”) does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the “Deloitte” name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see www.deloitte.com/about to learn more about our global network of member firms.

About Wound Management Technologies

With its number one goal of improving patient outcomes, Wound Management Technologies develops, markets and distributes biotechnology products to physicians, hospitals, and clinics. It has a strong history of developing long-term, strategic partnerships with a focus on products that fuse nature with science. Its primary products are in the $11 billion U.S. consumable medical device market and in the $1.5 billion biomaterials market. Wound Management Technologies sells and distributes the patent-protected and FDA-cleared CellerateRX® Surgical Activated Collagen® Adjuvant. Wound Management is anticipating new revenues from HemaQuell™ Resorbable Bone Hemostat. For more information, visit our website, www.wmgtech.com.

Information about Forward-Looking Statements

The statements in the press release that relate to the Company’s expectations with regard to the future impact on the Company’s results from new products in development and any other statements not constituting historical facts are “forward-looking statements,” within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the Company’s actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company’s operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company’s SEC filings, which could cause the Company’s actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.

Investor Contacts:

Investor Relations
800-205-7719
ir@wmgtech.com

SOURCE: Wound Management Technologies, Inc.

ReleaseID: 485441